U.S. drugmaker Merck & Co Inc reported a 55% rise in third-quarter profit on Thursday, helped by strong sales of blockbuster cancer drug Keytruda and recovery in demand for its non-COVID-19 vaccines, as well as lower expenses.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)